UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (X) Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period Ended July 31, 1997 () Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 1-8597 The Cooper Companies, Inc. - -----(Exact name of registrant as specified in its charter) Delaware 94-2657368 (State or other jurisdiction _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ - - - - - - - - -(I.R.S. Employer of incorporation or Identification No.) organization) 6140 Stoneridge Mall Rd., Suite 590, Pleasanton, CA 94588 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (510) 460-3600 Indicate by check mark whether the registrant (1) has filed all reports required

to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No

Indicate the number of shares outstanding of each of issuer's classes of common stock, as of the latest practicable date.

Common Stock, \$.10 par value	14,749,300 Shares
Class	Outstanding at
	August 22, 1997

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

INDEX

Page No.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Consolidated Condensed Statements of Income - Three and Nine Months Ended July 31, 1997 and 1996	3
Consolidated Condensed Balance Sheets - July 31, 1997 and October 31, 1996	4
Consolidated Condensed Statements of Cash Flows - Nine Months Ended July 31, 1997 and 1996	5-6
Notes to Consolidated Condensed Financial Statements	7-12
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	13-19
PART II. OTHER INFORMATION	
Item 6. Exhibits and Reports on Form 8-K	20
Signature	21
Index of Exhibits	22

PART I. FINANCIAL INFORMATION Item 1. FINANCIAL STATEMENTS THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Statements of Income (In thousands, except per share figures) (Unaudited)

	Three Months Ended July 31,		Nine Months Ended July 31,	
	1997 	1996	1997	1996
Net sales of products Net service revenue	\$24,951 13,998	\$18,001 10,870	\$ 62,608 38,380	\$47,339 30,556
Net operating revenue	38,949	28,871	100,988	77,895
Cost of products sold Cost of services provided Selling, general and admin-	8,277 12,107	5,507 10,027	19,412 34,162	14,252 29,164
istrative expense Research and development	10,173	7,283	27,213	21,627
expense Amortization of intangibles	487 503	294 286	1,225 1,195	887 717
Income from operations	7,402		17,781	11,248
Interest expense Other income, net	1,335 94	1,403 2	3,819 37	3,965 407
Income before income taxes Benefit of income taxes	6,161 (1,025)	4,073		7,690 (440)
Net income	\$ 7,186 ======	\$ 4,669 =====	\$ 15,869 ======	\$ 8,130 ======
Earnings per share	\$ 0.55 ======	\$ 0.40 =====	\$ 1.28 ======	\$ 0.69 =====
Number of shares used to compute earnings per share	12,981 ======	11,793 ======	12,365 =====	11,741 ======

See accompanying notes.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Balance Sheets (In thousands) (Unaudited)

	July 31, 1997	October 31, 1996
ASSETS		
Current assets:		
Cash and cash equivalents Trade receivables, net Inventories Other current assets	\$ 43,291 27,329 13,871 4,625	\$ 6,837 21,650 10,363 3,645
Total current assets	89,116	42,495
Property, plant and equipment at cost Less, accumulated depreciation and	54,938	49,306
amortization	16,451	14,632
	38,487	34,674
Goodwill and other intangibles, net Other assets	37,246 8,808	21,468 4,272
	\$ 173,657 =======	\$ 102,909 ======

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Short-term debt Trade accounts payable Other current liabilities Accrued income taxes		\$844 4,574 18,353 9,537
Total current liabilities	66,274	33,308
Long-term debt Other noncurrent liabilities	8,841 2,845	,
Total liabilities	77,960	87,579
Stockholders' equity:		
Common stock, \$.10 par value Additional paid-in capital Accumulated deficit Other	248, 532	1,167 184,300 (169,811) (326)
Total stockholders' equity	95,697	15,330
	\$ 173,657 ========	\$ 102,909 ======

See accompanying notes.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Statements of Cash Flows (In thousands) (Unaudited)

	Nine Month July	
	1997	
Net cash provided (used) by operating activities Cash flows from investing activities:	\$ 2,918	
Acquisitions Purchase of property, plant and	(7,145)	(3,796)
equipment Investment in escrow funds Other	(2,897) (358)	313
Net cash used by investing activities	(16,207)	(5,441)
Cash flows from financing activities:		
Proceeds from follow-on offering, net Payment on Wesley-Jessen promissory note Proceeds from industrial development note Payments of current installments of		
long-term debt Repayment of line of credit, net Proceeds from long-term debt Other		(1,768) (180) 1,320 99
Net cash provided (used) by financing activities		(529)
Net increase (decrease) in cash and cash equivalents	36,454	(8,064)
Cash and cash equivalents - beginning of period	6,837	11,207
Cash and cash equivalents - end of period	\$ 43,291 ======	

See accompanying notes.

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Statements of Cash Flows, Concluded (In thousands) (Unaudited)

Supplemental schedule of noncash investing and financing activities:

Acquisitions:	1997	1996
Fair value of assets	\$ 18,574	\$ 9,661
Less:		
Cash acquired Cash paid Company stock issued Notes issued	(45) (7,145) (4,662) (4,500)	(404) (3,796) (4,000)
Liabilities assumed and acquisition costs accrued	\$ 2,222 ======	\$ 1,461

In April 1996, the Company purchased the net assets of Unimar, Inc. by paying \$3.6 million in cash and issuing \$4 million in promissory notes. See Note 4 for a discussion of fiscal 1997 acquisitions.

See accompanying notes.

Note 1. General

The Cooper Companies, Inc., and its subsidiaries (the "Company") develop, manufacture and market healthcare products, including a range of hard and soft daily, flexible and extended wear contact lenses and diagnostic and surgical instruments and equipment. The Company also provides healthcare services through the ownership of psychiatric facilities and by providing outpatient and other ancillary services.

During interim periods, the Company follows the accounting policies set forth in its Form 10-K filed with the Securities and Exchange Commission. Readers are encouraged to refer to the Company's Form 10-K and its Annual Report to Stockholders for the fiscal year ended October 31, 1996 when reviewing this Form 10-Q. Quarterly results reported herein are not necessarily indicative of results to be expected for future quarters.

In the opinion of management, the accompanying unaudited consolidated condensed financial statements contain all adjustments necessary to present fairly the Company's consolidated financial position, results of operations and cash flows for those periods presented. Other than a reduction of \$2.1 million to the deferred tax asset valuation allowance recorded during the nine months ended July 31, 1997, based on Management's belief that the Company's future results will continue to compare favorably with those of the prior year, adjustments consist only of normal recurring items.

Note 2. Inventories

Inventories are stated at the lower of cost, determined on a first in, first out or average cost basis, or market.

The components of inventories are as follows:

	July 31, 1997	0ctober 31, 1996
	 (In th	iousands)
Raw materials Work-in-process Finished goods	\$ 2,907 1,324 9,640	\$ 2,318 1,028 7,017
	\$13,871 ======	\$10,363 =====

Note 3. Long-Term Debt

Long-term debt consists of the following:

	July 31, 1997	October 31, 1996
	 (In th	ousands)
10% Senior Subordinated		
Secured Notes due 2003	\$23,923	\$24,285
Promissory notes - Unimar	4,155	4,000
Promissory note - Wesley-Jessen		
Corporation ("W-J")	1,517	
County of Monroe Industrial		
Development Agency ("COMIDA")		
Bond	3,000	
HGA term loan	10,175	10,675
10-5/8% Convertible Sub-		
ordinated Reset Debentures		
due 2005	-	9,220
Other	470	584
	43,240	48,764
Less, current installments	34,399	844
	\$ 8,841	\$47,920
	======	======

On July 29, 1997, the Company announced that it had called for redemption on September 1, 1997, all \$21.9 million principal amount of its 10% Senior Subordinated Secured Notes due 2003 (the "Notes") at 100% of principal value plus unpaid interest through September 1, 1997. No interest will accrue or be paid on the Notes after September 1, 1997. It is anticipated that an extraordinary gain will be recorded in the fourth quarter as a result of the redemption.

The Company called for redemption on April 9, 1997 (the "Redemption Date") all \$9.3 million principal amount of its 10 5/8% Convertible Subordinated Reset Debentures due March 1, 2005 ("Debentures") at 100% of principal value, plus unpaid interest through the Redemption Date. On the Redemption Date, holders of 47 Debentures received cash totaling an aggregate redemption price of \$47,000 plus \$527 of interest. Holders of \$9.2 million of Debentures converted, at a conversion price of \$15 per share, all of their Debentures into shares of the Company's common stock. A total of 616,187 shares of the Company's common stock, plus \$253 of cash in lieu of fractional shares, were issued upon such conversions. The holders who converted forfeited the right to receive any interest on such Debentures after March 1, 1997. No gain or loss was recorded by the Company.

Promissory Note - W-J

The W-J promissory note, due March 17, 2001, was issued in conjunction with the acquisition of Natural Touch'r'. (See Note 4.) Interest on the W-J promissory note is payable semi-annually and accrues at a rate of 12% per annum, of which 8% per annum is payable in cash and 4% per annum is payable in kind. On July 31, 1997, the Company repaid \$3 million of the principal and associated unpaid interest.

COMIDA Bond

The COMIDA bond is a \$3 million Industrial Revenue Bond ("IRB") to finance the cost of plant expansion, building improvements, and the purchase of equipment related to CVI's Scottsville, New York, facility. Currently, interest on the IRB is adjusted weekly. The interest rate in effect on August 22, 1997 was 3.75% per annum. Interest rates have ranged from 3.45% to 4.85% per annum since the COMIDA bond was issued. Principal repayments are made quarterly, beginning July 1997 and ending October 2012. At July 31, 1997, unutilized proceeds of \$2.9 million from the IRB, which must be used for the aforementioned project, are carried in other assets. The IRB is secured by substantially all of CVI's rights to the facility.

A letter of credit was issued by KeyBank National Association ("KeyBank") to support certain obligations under the COMIDA bond. CVI is obligated to repay KeyBank for draws under and expenses incurred in connection with the letter of credit, pursuant to the terms of a Reimbursement Agreement, which is guaranteed by the Company. The Reimbursement Agreement contains customary provisions and covenants, including the maintenance of certain ratios and levels of net worth. CVI and COMIDA have granted a mortgage lien on the building and real estate located in Scottsville and a first lien security interest on the equipment purchased under the bond proceeds to KeyBank to secure payment under the Reimbursement Agreement.

Note 4. Acquisitions

NATURAL TOUCH'r' ACQUISITION

In March 1997, the Company acquired the United States rights to Natural Touch'r', a line of opaque, cosmetic contact lenses, from W-J for \$7.5 million (\$3 million in cash and a \$4.5 million promissory note, \$3 million of which was repaid on July 31, 1997)

plus an ongoing royalty ranging from 3% to 8% per annum on sales of Natural Touch'r' products other than those supplied by W-J. The Company recorded intangible assets of \$8 million for the patents, trademarks and distribution rights, which will be amortized over 7 to 15 years (the life of the patents or trademark).

Presently, a subsidiary of W-J manufactures and supplies the Company with the products for the Natural Touch'r' line. A divestiture order issued by the Federal Trade Commission (the "FTC") in connection with the acquisition of the Natural Touch'r' line requires that the Company either develop on its own the manufacturing capabilities to produce the Natural Touch'r' line or find a suitable third-party manufacturer to produce it. The FTC could require the Company to divest itself of the Natural Touch'r' line if the Company has not either developed manufacturing capabilities that meet United States Food and Drug Administration ("FDA") approval or found a suitable third-party manufacturer meeting FDA approval within 18 months from the closing date (which deadline may be extended by an additional 24 months.

MARLOW ACQUISITION

In April 1997, the Company acquired Marlow Surgical Technologies, Inc., ("Marlow"), a gynecology products company, for approximately \$3.2 million in cash, liquidation of \$900,000 of Marlow debt and 144,800 shares of the Company's common stock valued at \$2.9 million at closing. As part of the acquisition, the Company agreed to issue an additional \$500,000 of its common stock (valued as of the closing) on the third anniversary of the closing, subject to reduction by the amount of any obligations of the seller to indemnify the Company in connection with the acquisition. Also, the Company has guaranteed that the total value of the shares of its common stock issued or to be issued in the acquisition (valued at \$3.4 million in total at closing) will appreciate by \$1.3 million by the third anniversary of the acquisition. This guarantee has been included in the purchase price, with a corresponding credit to additional paid in capital. The acquisition has been accounted for as a purchase. Initially, \$8.4 million has been ascribed to goodwill, which is being amortized over 20 years.

Note 5. Cooper Life Sciences

In April 1997, the Company issued two term notes to Cooper Life Sciences, Inc. ("CLS") totaling \$5 million and bearing interest at the prime rate per annum. The CLS term notes were due January 1998. On July 31, 1997, the notes plus accrued interest were repaid from the proceeds of the follow-on offering. (See Note 6.) CLS owns approximately 1,192,133 shares (or

approximately 8%) of the Company's common stock. Two members of the Company's Board of Directors were designated by CLS, and one member of the Company's board owns the majority of the capital stock of CLS. In addition, two of these directors are also directors of CLS.

Note 6. Supplementary Earnings Per Share Information

On July 23, 1997, the Company filed with the Securities and Exchange Commission a prospectus supplement for the sale of 2,000,000 shares of the Company's common stock at the offering price of \$23 1/2 per share. The Company sold 2,300,000 shares of common stock (including 300,000 shares for over allotment). The proceeds from the offering of \$50.5 million, net of underwriters discount and transaction costs of \$3.6 million, was used and will be used to repay outstanding indebtedness.

The following presents supplementary earnings per share information assuming the proposed offering and the repayment of \$34.7 million and \$38.2 million of debt, respectively, on the first day of fiscal 1996 and fiscal 1997:

	Year Ended October 31, 1996	Nine Months Ended July 31, 1997
Earnings per share:		
From continuing operations Extraordinary item(1)	\$ 1.55 .14	\$ 1.32 .10
Earnings per share	\$ 1.69 ======	\$ 1.42 ======
Number of shares used to compute earnings per share (in thousands):		
Historical Shares, the proceeds of which are assumed to be used to repay outstanding	11,761	12,365
indebtedness	1,584	1,742
Total	13,345 ======	14,107

(1) Represents the per share amount related to a net extraordinary gain, net of taxes and prepayment penalties, of \$1.4 million for the nine months ended July 31, 1997 and \$1.8 million for the year ended October 31, 1996 related to the assumed extinguishment of debt, as if such extinguishment had occurred on the first day of the periods presented.

- ------

Note 7. Impact of Statements of Financial Accounting Standards Issued But Not Adopted

In February 1997, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 128, "Earnings per Share" ("SFAS 128"), which will be effective for financial statements for periods ending after December 15, 1997, including interim periods, and established standards for computing and presenting earnings per share. Earlier application is not permitted. Beginning with its unaudited consolidated condensed financial statements for the first quarter of fiscal 1998, the Company will make the required disclosures of basic and diluted earnings per share and provide a reconciliation of the numerator and denominator of its basic and diluted earnings per share computations. All prior period earnings per share data will be restated by the Company upon adoption of SFAS 128. The Company expects that basic earnings per share figures to be reported under SFAS 128 will be somewhat higher than the figures historically reported, due to the removal of common stock equivalents from the calculation of average shares and that diluted earnings per share will not differ materially from historically reported figures.

In June 1997, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 130 "Reporting Comprehensive Income" ("SFAS 130") which will be effective for financial statements for fiscal years beginning after December 15, 1997, and establishes standards for reporting and display of comprehensive income and its components in a full set of general purpose financial statements. Earlier application is permitted. The Company will make the required reporting of comprehensive income beginning with its consolidated financial statements for the fiscal year beginning November 1, 1998. Upon adoption, reclassification of comparative financial statements for prior periods to reflect application of the provisions of SFAS 130 is required. The Company does not expect that the adoption of this statement will have a material impact on its financial position or results of operations.

In June 1997, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 131 "Disclosures about Segments of an Enterprise and Related Information" ("SFAS 131") which will be effective for financial statements for periods beginning after December 15, 1997, and establishes standards for disclosures about segments of an enterprise. Earlier application is encouraged. The Company will make the required disclosures under SFAS 131 beginning with its consolidated financial statements for the year ending October 31, 1999. Upon adoption, comparative information for earlier years is to be restated.

References to Note numbers below are references to the Notes to Consolidated Condensed Financial Statements located in Item 1.

RESULTS OF OPERATIONS

Three and Nine Months Ended July 31, 1997 Compared with Three and Nine Months Ended July 31, 1996.

NET SALES OF PRODUCTS: Net sales of products increased by \$7 million or 39% and \$15.3 million or 32% for the three and nine months ended July 31, 1997, respectively.

			(Dollars i	in 000's)		
	Thr	ee Months End	ed	Nin	e Months Ende	d
		July 31,			July 31,	
	1997	1996	% Incr.	1997	1996	% Incr.
CVI*	\$17,815	\$12,963	37%	\$44,922	\$35,191	28%
CSI**	7,136	5,038	42%	17,686	12,148	46%
	\$24,951	\$18,001	39%	\$62,608	\$47,339	32%
	======	======		======	======	

* CVI = CooperVision, Inc.

** CSI = CooperSurgical, Inc.

Net sales of CVI increased both domestically and in Canada. The primary contributors to the growth included increased sales of the Preference'r' spherical and the Preference Toric'tm') product lines, which together grew by approximately 48% over the comparable nine-month period. Sales of toric lenses to correct astigmatism, CVI's leading product group, grew 40% over the comparable nine-month period and accounted for 52% of its sales, up from 48% last year. In March 1997, the Company acquired Natural Touch'r', a line of opaque, cosmetic contact lenses (see Note 4), which contributed over \$2.1 million of sales in fiscal 1997. These increases were partially offset by anticipated decreases in sales of more mature product lines.

At CSI, year-to-date net sales increased by 46%. CSI's gynecology product lines grew by approximately 60% over the period primarily due to sales of products acquired in April 1996 (Unimar'r') and April 1997 (Marlow). (See Note 4.)

NET SERVICE REVENUE: Hospital Group of America, Inc.'s ("HGA") net service revenue for the nine-month period of \$38.4 million increased by 26% over the prior year, as revenue generated by Hampton Hospital improved dramatically following a successful transition of the physician group begun in the first quarter of fiscal 1996.

Revenue continues to be pressured by the trend toward increased managed care, which results in decreased per diems and pressures average lengths of stay. Management is mitigating these by increasing the number of admissions to its hospitals, improving its payer mix and expanding outpatient and other ancillary services. For the nine-month period ended July 31, 1997, admissions are up 22%, and outpatient visits are up 57% over the same 1996 period. In April 1997, HGA opened the Midwest Center for Youth and Families, a 50-bed residential treatment facility in Kouts, Indiana, and set up a new management services division, which contracts to manage behavioral health programs.

		(Dollars in 000's)					
	Thre	Three Months Ended July 31,			Nine Months Ended July 31,		
	1997 	1996	% Incr. (Decr.)	1997 	1996	%Incr. (Decr.)	
Licensed inpatient							
beds Inpatient	319*	269	19%	319*	269	19%	
admissions Total inpatient	1,616	1,373	18%	4,711	3,847	22%	
days Average length of stay	20,392	15,932	28%	55,669	46,279	20%	
(days) Total outpatient	11.6	11.6		11.4	12.2	(7%)	
visits	20,930	11,884	76%	54,081	34,476	57%	

*Midwest Center for Youth and Families opened in April 1997, adding 50 licensed inpatient beds.

COST OF PRODUCTS SOLD: Gross profit (net sales of products less cost of products sold) as a percentage of net sales of products ("margin") was as follows:

	Margin % Three Months Ended July 31,		Margin % Nine Months Ended July 31,	
	1997	1996	1997	1996
CVI	73	77	76	76
CSI	52	51	52	51
Consolidated	67	69	69	70

CVI's margin for the third quarter 1997 was decreased by: 1) a write off of approximately \$300,000 of inventory and other costs related to an unsuccessful attempt to gain access to the over-the-counter ophthalmic pharmaceutical market in Canada and 2) increased sales of lower margin Natural Touch'r' products purchased in March 1997.

Margin improved at CSI primarily due to cost reduction programs associated with Unimar'r' products, acquired in April 1996.

COST OF SERVICES PROVIDED: Cost of services provided represents all normal operating costs (other than financing costs and amortization of intangibles) incurred by HGA in generating net service revenue. The result of subtracting cost of services provided from net service revenue is \$4.2 million, or 11%, and \$1.4 million, or 5%, of net service revenue in the first nine months of 1997 and 1996, respectively. The increase in profit resulted primarily from improved revenue, particularly at Hampton Hospital and increased outpatient visits that generate an operating margin approaching 20%, and with the benefit of concurrent cost controls.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSE: Selling, general and administrative (SG&A) expense by business unit and corporate ("HQ") were as follows:

			(Dollars i	n 000's)		
	Three Months Ended July 31,			Nir	Nine Months Ended July 31,	ed
	1997	1996	% Incr. (Decr.)	1997	1996	% Incr. (Decr.)
CVI CSI HQ/Other	\$ 6,271 2,333 1,569	\$ 4,051 1,804 1,428	55% 29% 10%	\$16,586 6,303 4,324	\$12,567 4,518 4,542	32% 40% (5%)
	\$10,173 ======	\$ 7,283	40%	\$27,213 ======	\$21,627 ======	26%

SG&A expense for the three- and nine-month periods increased 40% and 26%, respectively, largely as a result of: (1) higher selling, promotion and distribution costs at CVI, which contributed to a 28% year-to-year increase in sales and (2) CSI SG&A expenses related to the Unimar and Marlow acquisitions, which contributed to CSI's 46% year-to-year revenue increase. The decrease in HQ/Other SG&A expenses for the nine-month period is primarily the result of consolidating the executive headquarters.

INCOME FROM OPERATIONS: As a result of the variances discussed above, income from operations improved by \$1.9 million, or 35%, and \$6.5 million, or 58%, for the three-and nine-month periods, respectively. Income (loss) from operations by business unit and HQ was as follows:

			(Dollars ir	1 000's)		
	Thr	ee Months Ende July 31,	ed	Nir	e Months End July 31,	ed
	1997	1996	Incr. (Decr.)	1997	1996	Incr.
CVI	\$ 6,235	\$ 5,625	\$ 610	\$16,230	\$13,505	\$ 2,725
CSI	890	491	399	1,792	1,064	728
HGA	1,846	792	1,054	4,083	1,238	2,845
HQ/Other	(1,569)	(1,434)	(135)	(4,324)	(4,559)	235
	\$ 7,402	\$ 5,474	\$ 1,928	\$17,781	\$11,248	\$ 6,533
	=====	======	======	======	======	======

INTEREST EXPENSE: The decrease in interest expense is primarily due to: (1) reduced interest rates on the HGA term loan and the CVI line of credit, (2) the Debenture redemption and (3) reduced borrowing on the line of credit at CVI. These savings were partially offset by interest charges associated with the Unimar Note, W-J Note, CLS Note and COMIDA Bond. (See Notes 3 and 5.)

PROVISION FOR INCOME TAXES: The 1997 provision for federal and state taxes for the first nine months of \$445,000 was offset by a reversal of \$215,000 of tax accruals no longer required, and the recognition of an additional benefit of \$2.1 million from reducing the valuation allowance against the net deferred tax assets, based on Management's belief that the Company's future results will continue to compare favorably with those of the prior year. The Company recorded no deferred tax benefit prior to the fourth quarter of its 1996 fiscal year. The tax provision for the first nine months of fiscal 1996 was for federal and state taxes of \$175,000, offset by a reversal of \$615,000 of tax accruals no longer required.

CAPITAL RESOURCES & LIQUIDITY

OVERVIEW: During the third quarter, the Company raised \$51.2 million in a public offering of 2.3 million shares of its common stock. The offering was underwritten by Deutsche Morgan Grenfell and PaineWebber Incorporated. As indicated in the prospectus, the Company is using the proceeds to repay outstanding indebtedness. Since the follow-on offering, the Company has repaid approximately \$22 million of debt (approximately \$12 million of which was repaid in the third quarter) and has called for redemption on September 1, 1997, all \$21.9 million principal amount of its 10% Senior Subordinated Secured Notes due 2003. Following these repayments, the Company's debt will be reduced to approximately \$9.1 million.

As previously announced, the Company expects to complete a \$50 million secured revolving credit facility in its fourth fiscal quarter. The facility would have a term of five years, with borrowings having interest rates ranging from 0.5% to 2.25% over the London Interbank Offered Rates (LIBOR) depending on certain financial ratios. The thirty day LIBOR was approximately 5 5/8% on August 25, 1997. The Company intends to use this debt financing to fund acquisitions and for general corporate purposes.

In April 1997, the Company redeemed or converted into common stock all \$9.3 million principal amount of its 10-5/8% Convertible Subordinated Reset Debentures due 2005 (see Note 3), in a transaction that is not expected to be dilutive to the Company's 1997 earnings.

As a result of these transactions and three quarters of profitable operations in fiscal 1997 (bringing the number of consecutive profitable quarters to seven), the Company's balance sheet has been dramatically strengthened since the 1996 fiscal year end. The Company's debt to equity ratio has improved from 3.2 to 1 at October 31, 1996 to 0.4 to 1 at July 31, 1997, with net worth up over 500% to \$95.7 million from \$15.3 million. Also, cash, cash equivalents and restricted cash net of debt has improved from a net debt position of \$41.9 million at October 31, 1996 to a net cash, cash equivalents and restricted cash position of \$2.9 million at July 31, 1997. With a competitively priced revolving credit facility virtually in place and operations that should provide sufficient cash to fund general corporate activities, management believes that the Company is well positioned to pursue the acquisition opportunities it is currently evaluating.

OPERATING CASH FLOWS: Cash provided by operating activities for the nine months ended July 31, 1997 was \$2.9 million compared with \$2.1 million used by operating activities in the first nine months of fiscal 1996. Operating activities provided \$3.5 million for the fiscal year 1996.

The primary uses of cash for operating activities in the first nine months of 1997 included payments of \$4.7 million associated with settlements of certain disputes and payments totaling \$2 million to fund fiscal 1996 entitlements under the Company's annual bonus plans. Cash disbursements for 1996 operating activities for the same period included payments of \$4.9 million associated with settlements of certain disputes and payments totaling \$2 million to fund fiscal 1995 entitlements under the Company's annual bonus plans.

INVESTING CASH FLOWS: Primary uses of cash for investing activities for the nine months ended July 31, 1997 included purchases of property, plant and equipment of \$5.8 million, of which approximately \$1.3 million relates to CooperVision's expansion of the Scottsville, New York, plant and approximately \$1.7 million related to the construction of the Midwest Center for Youth and Families, a residential treatment center that HGA opened in April 1997. Investing activities also included cash paid for acquisitions of \$3 million for Natural Touch(R), a line of opaque contact lenses from Wesley-Jessen and \$4.1 million for Marlow Surgical Technologies, Inc., a gynecology products company (see Note 4), investments in escrow funds of \$2.9 million and other investment activities of \$0.4 million.

FINANCING CASH FLOWS: Financing activities primarily related to net proceeds generated from the follow-on offering of \$50.5 million (see Note 6), and the \$3 million industrial development note and paydown of the Wesley-Jessen Corporation promissory note by \$3 million (see Note 3).

IMPACT OF STATEMENTS OF FINANCIAL ACCOUNTING STANDARDS ISSUED BUT NOT ADOPTED

See Note 7 for a discussion of the impact of the following Statements of Financial Accounting Standards ("SFAS") issued but not adopted:

SFAS 128 "Earnings Per Share" SFAS 130 "Reporting Comprehensive Income" SFAS 131 "Disclosure About Segments of an Enterprise and Related Information"

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations, Concluded

FORWARD-LOOKING STATEMENTS

Statements contained in this document that are not based on historical fact may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by use of forward-looking terminology such as "may," "will," "expect," "estimate," "anticipate," "continue" or similar terms. Certain statements in the Company's periodic and other filings with the Securities and Exchange Commission, including all the statements under the headings "Risk Factors" and "Recent Developments" in the Prospectus and Prospectus Supplement for shares of the Company's common stock attached as an exhibit to a Form 8-K filed July 23, 1997, constitute cautionary statements identifying important factors that could cause actual results to differ materially from those contained in the forward-looking statements. Additional factors that could cause or contribute to differences include: major changes in business conditions and the economy in general; loss of key members of senior management; new competitive inroads; costs to integrate acquisitions; decisions to invest in research and development projects; dilution to earnings per share associated with acquisitions or stock issuance; regulatory issues; unexpected changes in reimbursement rates and payor mix; costs associated with debt restructuring; unforeseen litigation and decisions to divest businesses. Future results are also dependent on each subsidiary of the Company meeting specific objectives.

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits

Exhibit Number	Description
10.19	Letter Agreement Dated April 11, 1997, By and Between Mark R. Russell and Hospital Group of America, Inc.
11	Calculation of Earnings Per Share.

27 Financial Data Schedule.

(b) The Company filed the following reports on Form 8-K during the period from May 1, 1997 to July 31, 1997.

Date of Report	Item Reported
May 21, 1997	Item 5. Other Events.
June 2, 1997	Item 5. Other Events.
July 22, 1997	Item 5. Other Events.
July 23, 1997	Item 5. Other Events.
July 29, 1997	Item 5. Other Events.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

The Cooper Companies, Inc. -----(Registrant)

Date: August 29, 1997

/s/ Robert S. Weiss Executive Vice President, Treasurer and Chief Financial Officer

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Index of Exhibits

Exhibit No.		Page No.
10.19	Letter Agreement Dated April 11, 1997, By and Between Mark R. Russell and Hospital Group of America, Inc.	
11	Calculation of Earnings Per Share.	
27	Financial Data Schedule.	
	22	

STATEMENT OF DIFFERENCES

The trademark symbol shall be expressed as	tm'
The registered trademark symbol shall be expressed as	'r'

Exhibit 10.19 THE COOPER COMPANIES, INC. AND SUBSIDIARIES

April 11, 1997

Mr. Mark R. Russell c/o Hospital Group of America, Inc. 1256 Drummers Lane, Suite 107 Wayne, PA 19087

Re: Employment Agreement with Hospital Group of America, Inc.

Dear Mark:

Reference is made to the Employment Agreement ("Employment Agreement") dated as of May 27, 1992 between you and Hospital Group of America, Inc. ("HGA"), as amended by the letter agreement effective as of June 15, 1993 among you, HGA and PSG Management, Inc. ("PSG") and as further amended by Steven G. Singer's memorandum to you dated November 12, 1993 and by the letter agreements effective as of January 11, 1996 and April 15, 1996 among you, HGA and PSG.

HGA and PSG each hereby ratifies and confirms the Employment Agreement in all respects, except that effective as of the date hereof, clause (a) of Section 1 of the Employment Agreement shall be amended to read in its entirety as follows: (a) July 1, 1999, and'.

The provisions of Sections 9,10 and 11(c) of the Employment Agreement shall be deemed incorporated in this Agreement as if fully set forth herein.

Kindly evidence your agreement with the foregoing amendments to the Employment Agreement by signing in the space provided below for your signature.

Very truly yours,

HOSPITAL GROUP OF AMERICA, INC.

By: /s/ Carol R Kaufman

PSG MANAGEMENT, INC.

By: /s/ Carol R Kaufman

Agreed to and accepted this 14th day of April, 1997, to be effective as of the date set forth above.

/s/ Mark R. Russell

Mark R. Russell

Exhibit 11 THE COOPER COMPANIES, INC. AND SUBSIDIARIES Calculation of Earnings Per Share (In thousands, except per share figures) (Unaudited)

	Three Months Ended July 31, 1997 1996		Nine Months Ended July 31, 1997 1996	
Primary: Net income	\$ 7,186 ======	\$ 4,669 ======	\$15,869 ======	\$ 8,130 ======
Weighted average number of common shares outstanding Number of common equivalent shares using the treasury	12,645	11,657	12,083	11,639
stock method	336	136	282	102
Average number of common shares used to compute earnings per share Earnings per share	12,981 ====== \$.55 ======	11,793 ====== \$.40 ======	12,365 ====== \$ 1.28 ======	11,741 ====== \$.69 ======
Fully Diluted:				
Net income	\$ 7,186 ======	\$ 4,669 ======	\$15,869 ======	\$ 8,130 ======
Weighted average number of common shares outstanding Number of common equivalent shares using the treasury	12,645	11,657	12,083	11,639
stock method	437	168	352	154
Average number of common shares used to compute earnings per share		11,825 ======		11,793 ======
Earnings per share	\$.55 ======	\$.39 ======	\$ 1.28 ======	\$.69 =====

```
5
1,000
```

```
9-MOS
       OCT-31-1997
             JUL-31-1997
                   43,291
0
                 29,922
2,593
13,871
               54,938
16,451
173.657
              89,116
             173<sup>°</sup>, 657
        66,274
                        8,587
              0
                        0
                       1,475
                    94,222
173,657
                      62,608
             100,039
                        19,412
                 53,574
0
                   0
             3,819
               13,999
          (1,870)
15,869
0
0
                           0
                  15,869
1.28
                   1.28
```